» Articles » PMID: 26349075

Network Meta-analysis of Randomized Trials on the Safety of Vascular Closure Devices for Femoral Arterial Puncture Site Haemostasis

Overview
Journal Sci Rep
Specialty Science
Date 2015 Sep 9
PMID 26349075
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The safety of vascular closure devices (VCDs) is still debated. The emergence of more related randomized controlled trials (RCTs) and newer VCDs makes it necessary to further evaluate the safety of VCDs. Relevant RCTs were identified by searching PubMed, EMBASE, Google Scholar and the Cochrane Central Register of Controlled Trials electronic databases updated in December 2014. Traditional and network meta-analyses were conducted to evaluate the rate of combined adverse vascular events (CAVEs) and haematomas by calculating the risk ratios and 95% confidence intervals. Forty RCTs including 16868 patients were included. Traditional meta-analysis demonstrated that there was no significant difference in the rate of CAVEs between all the VCDs and manual compression (MC). Subgroup analysis showed that FemoSeal and VCDs reported after the year 2005 reduced CAVEs. Moreover, the use of VCDs reduced the risk of haematomas compared with MC. Network meta-analysis showed that AngioSeal, which might be the best VCD among all the included VCDs, was associated with reduced rates of both CAVE and haematomas compared with MC. In conclusion, the use of VCDs is associated with a decreased risk of haematomas, and FemoSeal and AngioSeal appears to be better than MC for reducing the rate of CAVEs.

Citing Articles

Ambulatory pulmonary vein isolation workflow using the Perclose ProglideTM suture-mediated vascular closure device: the PRO-PVI study.

Fabbricatore D, Buytaert D, Valeriano C, Mileva N, Paolisso P, Nagumo S Europace. 2023; 25(4):1361-1368.

PMID: 36793243 PMC: 10105833. DOI: 10.1093/europace/euad022.


Vascular Accesses in Cardiac Stimulation and Electrophysiology: An Italian Survey Promoted by AIAC (Italian Association of Arrhythmias and Cardiac Pacing).

Ziacchi M, Placci A, Angeletti A, Quartieri F, Balla C, Virzi S Biology (Basel). 2022; 11(2).

PMID: 35205131 PMC: 8869488. DOI: 10.3390/biology11020265.


2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Cronin E, Bogun F, Maury P, Peichl P, Chen M, Namboodiri N J Interv Card Electrophysiol. 2020; 59(1):145-298.

PMID: 31984466 PMC: 7223859. DOI: 10.1007/s10840-019-00663-3.


2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary.

Cronin E, Bogun F, Maury P, Peichl P, Chen M, Namboodiri N J Interv Card Electrophysiol. 2020; 59(1):81-133.

PMID: 31960344 PMC: 7508755. DOI: 10.1007/s10840-019-00664-2.


An update on the use of an arterial closure device following femoral arterial puncture in children.

Smith J, Monroe E, Shivaram G, Shaw D, Koo K Pediatr Radiol. 2019; 49(9):1217-1221.

PMID: 31190109 DOI: 10.1007/s00247-019-04442-0.


References
1.
Baim D, Knopf W, Hinohara T, Schwarten D, Schatz R, Pinkerton C . Suture-mediated closure of the femoral access site after cardiac catheterization: results of the suture to ambulate aNd discharge (STAND I and STAND II) trials. Am J Cardiol. 2000; 85(7):864-9. DOI: 10.1016/s0002-9149(99)00882-6. View

2.
Kussmaul 3rd W, Buchbinder M, Whitlow P, Aker U, Heuser R, King S . Rapid arterial hemostasis and decreased access site complications after cardiac catheterization and angioplasty: results of a randomized trial of a novel hemostatic device. J Am Coll Cardiol. 1995; 25(7):1685-92. DOI: 10.1016/0735-1097(95)00101-9. View

3.
Wetter D, Rickli H, von Smekal A, Amann F . Early sheath removal after coronary artery interventions with use of a suture-mediated closure device: clinical outcome and results of Doppler US evaluation. J Vasc Interv Radiol. 2000; 11(8):1033-7. DOI: 10.1016/s1051-0443(07)61334-7. View

4.
Diaz de la Llera L, Fournier Andray J . [Early deambulation following cardiac catheterization by the use of 6 Fr Angio-Seal, a new hemostatic percutaneous puncture closure device]. Rev Esp Cardiol. 2002; 54(12):1406-10. DOI: 10.1016/s0300-8932(01)76523-2. View

5.
. Assessment of the safety and efficacy of the DUETT vascular hemostasis device: final results of the safe and effective vascular hemostasis (SEAL) trial. Am Heart J. 2002; 143(4):612-9. DOI: 10.1067/mhj.2002.121464. View